Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis : Sandoz acquires US distribution rights to two key hospital injectable medicines, reinforcing strategic focus on key growth segment

share with twitter share with LinkedIn share with facebook
share via e-mail
03/24/2020 | 07:28am EDT

Princeton - Sandoz today announced that it has acquired the distribution rights in the United States for daptomycin 500mg injection and fosaprepitant 150mg for injection from BE Pharmaceuticals AG, to reinforce the company's strategy to grow its injectables portfolio and overall offerings in the hospital setting.

Daptomycin is a naturally occurring lipopeptide antibiotic used in the treatment of infections caused by Gram-positive bacteria and is the generic version of Cubicin. Fosaprepitant is an antiemetic drug used in the prevention of nausea and vomiting associated with certain chemotherapies, administered as IV infusion, and is the generic prodrug of Emend for injection.

'These medicines strategically support our institutional portfolio, add value for our sales force, and increase our overall offerings in the hospital setting,' said Carol Lynch, President, Sandoz Inc. 'Our ambition is to make Sandoz the world's leading and most valued generics company. To realize that ambition in the US market, we are focusing on specific segments such as hospitals and oncology clinics with generic and branded generic injectables, where we can do the most to pioneer access for patients.'

Under the distribution and supply agreements, Sandoz acquires the distribution rights in the United States for daptomycin 500mg injection and fosaprepitant 150mg for injection from BE Pharmaceuticals AG, which retains responsibility for manufacturing the products and managing the regulatory approval process.


This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'plan,' 'may,' 'could,' 'would,' 'expect,' 'anticipate,' 'seek,' 'look forward,' 'believe,' 'committed,' 'investigational,' 'pipeline,' 'launch,' or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the daptomycin and fosaprepitant products or regarding the transaction described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the expected benefits and synergies from the transaction will be achieved in the expected timeframe, or at all. In particular, our expectations regarding the transaction and such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic versions of such products; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit Sandoz from selling its products; general political and economic conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sandoz

Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world's leading and most valued generics company. Our broad portfolio of high-quality medicines, covering all major therapeutic areas, accounted for 2019 sales of USD 9.7 billion. Sandoz is headquartered in Holzkirchen, in Germany'sGreater Munich area.


Antonio Ligi

Tel: +41 79 7233681

Email: antonio.ligi@novartis.com

(C) 2020 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVARTIS AG
05/21GLOBAL MARKETS LIVE: Apple and Google unveil their Covid-19 contact tracing s..
05/21NOVARTIS AG : UBS reaffirms its Neutral rating
05/20NOVARTIS : AveXis receives EC approval and activates 'Day One' access program fo..
05/19More Than 150 Companies Call for Green Coronavirus Recovery
05/19NOVARTIS : Zolgensma Gets Conditional EU Approval
05/17Temporary layoff schemes no cure-all in slow COVID recovery
05/14NOVARTIS : Sandoz Glatopa demonstrates trend towards lower relapse rates and cos..
05/11NOVARTIS AG : UBS reaffirms its Neutral rating
05/08NOVARTIS AG : Sell rating from JP Morgan
05/07GLOBAL MARKETS LIVE: Merger between 02 and Virgin goes ahead
More news
Financials (USD)
Sales 2020 50 047 M
EBIT 2020 15 196 M
Net income 2020 9 407 M
Debt 2020 17 505 M
Yield 2020 3,65%
P/E ratio 2020 20,7x
P/E ratio 2021 17,3x
EV / Sales2020 4,11x
EV / Sales2021 3,79x
Capitalization 188 B
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 100,41 $
Last Close Price 85,50 $
Spread / Highest target 51,5%
Spread / Average Target 17,4%
Spread / Lowest Target -9,97%
EPS Revisions
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-10.58%186 299
JOHNSON & JOHNSON-1.03%380 356
ROCHE HOLDING AG10.48%303 907
PFIZER, INC.-4.29%208 306
MERCK & CO., INC.-16.03%192 766
ABBVIE INC.4.02%162 312